Study on finerenone for kidney health in type 2 diabetes
Treatments studied
Part of Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests if a medicine called finerenone can protect kidney function in people with type 2 diabetes and early-to-moderate chronic kidney disease. It may be an option if you are already on blood pressure medication and have some protein in your urine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with type 2 diabetes.
- You are 18 years or older.
- Your urine has at least a small amount of protein (UACR 30 mg/g or more) and your kidney function (eGFR) is 30 or higher for over 3 months.
- You have been taking a stable dose of an ACE inhibitor or ARB (blood pressure medicines) for at least 4 weeks before joining.
- You are willing to follow the study plan and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a medication called finerenone to see how well it helps people with type 2 diabetes who also have chronic kidney disease. Researchers are looking at how the drug affects kidney function and related health factors.
This observational study tracks how well finerenone (a kidney-protective medication) works in adults with type 2 diabetes and chronic kidney disease in Spain. Researchers will measure changes in kidney function and disease risk over time to better understand the medication's real-world benefits.
This study looks at how the medication finerenone works in everyday medical practice for people with type 2 diabetes and certain stages of chronic kidney disease. It aims to see how safe and effective the treatment is outside of a clinical trial setting.
This trial tests if finerenone can protect kidneys in people with chronic kidney disease who are not taking common blood pressure medications called ACE inhibitors, ARBs, or renin inhibitors. It may help slow kidney damage.
This study is for people in South Korea who have chronic kidney disease and type 2 diabetes and are already taking or about to start the medicine finerenone (Kerendia). The goal is to see how well finerenone works in everyday medical care, outside of a strict research setting.
This trial tests if a drug called finerenone can help protect the retina (the light-sensing part of the eye) in people with chronic kidney disease. It may be a way to prevent eye damage alongside kidney treatment.
Hear when a new Chronic kidney disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.